AR121912A1 - Compuestos terapéuticos - Google Patents
Compuestos terapéuticosInfo
- Publication number
- AR121912A1 AR121912A1 ARP210101080A ARP210101080A AR121912A1 AR 121912 A1 AR121912 A1 AR 121912A1 AR P210101080 A ARP210101080 A AR P210101080A AR P210101080 A ARP210101080 A AR P210101080A AR 121912 A1 AR121912 A1 AR 121912A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- tetrahydroisoquinoline
- methylcyclohexane
- fluoro
- carbonyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 abstract 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 abstract 1
- -1 5,6-dihydro-4H-pyrrolo[1,2-c][1,2,3]triazol-3-yl Chemical group 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005863.2A GB202005863D0 (en) | 2020-04-22 | 2020-04-22 | Therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121912A1 true AR121912A1 (es) | 2022-07-20 |
Family
ID=70860156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101080A AR121912A1 (es) | 2020-04-22 | 2021-04-22 | Compuestos terapéuticos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230167084A1 (enExample) |
| EP (1) | EP4139294B1 (enExample) |
| JP (1) | JP7679400B2 (enExample) |
| KR (1) | KR20230004720A (enExample) |
| CN (1) | CN115667243B (enExample) |
| AR (1) | AR121912A1 (enExample) |
| AU (1) | AU2021259366A1 (enExample) |
| BR (1) | BR112022021244A2 (enExample) |
| CA (1) | CA3174361A1 (enExample) |
| ES (1) | ES3032247T3 (enExample) |
| GB (1) | GB202005863D0 (enExample) |
| IL (1) | IL297434A (enExample) |
| MX (1) | MX2022013398A (enExample) |
| PH (1) | PH12022552775A1 (enExample) |
| WO (1) | WO2021214470A1 (enExample) |
| ZA (1) | ZA202211465B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64836B1 (sr) * | 2018-10-22 | 2023-12-29 | C4X Discovery Ltd | Terapijska jedinjenja |
| AU2023204960A1 (en) * | 2022-01-07 | 2024-05-16 | Chugai Seiyaku Kabushiki Kaisha | Nitrogen-containing heterocyclic compound having nrf2 activation effect |
| TW202604491A (zh) | 2024-05-13 | 2026-02-01 | 瑞典商阿斯特捷利康公司 | 用於療法中之ｋｅａｐ１抑制劑 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003041641A2 (en) * | 2001-11-09 | 2003-05-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| KR20180017038A (ko) * | 2015-06-15 | 2018-02-20 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| RS64836B1 (sr) * | 2018-10-22 | 2023-12-29 | C4X Discovery Ltd | Terapijska jedinjenja |
-
2020
- 2020-04-22 GB GBGB2005863.2A patent/GB202005863D0/en not_active Ceased
-
2021
- 2021-04-22 ES ES21723350T patent/ES3032247T3/es active Active
- 2021-04-22 MX MX2022013398A patent/MX2022013398A/es unknown
- 2021-04-22 US US17/920,226 patent/US20230167084A1/en active Pending
- 2021-04-22 CA CA3174361A patent/CA3174361A1/en active Pending
- 2021-04-22 KR KR1020227040550A patent/KR20230004720A/ko active Pending
- 2021-04-22 PH PH1/2022/552775A patent/PH12022552775A1/en unknown
- 2021-04-22 EP EP21723350.1A patent/EP4139294B1/en active Active
- 2021-04-22 WO PCT/GB2021/050973 patent/WO2021214470A1/en not_active Ceased
- 2021-04-22 IL IL297434A patent/IL297434A/en unknown
- 2021-04-22 CN CN202180031435.0A patent/CN115667243B/zh active Active
- 2021-04-22 JP JP2022564519A patent/JP7679400B2/ja active Active
- 2021-04-22 AU AU2021259366A patent/AU2021259366A1/en active Pending
- 2021-04-22 BR BR112022021244A patent/BR112022021244A2/pt unknown
- 2021-04-22 AR ARP210101080A patent/AR121912A1/es unknown
-
2022
- 2022-10-19 ZA ZA2022/11465A patent/ZA202211465B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022021244A2 (pt) | 2022-12-06 |
| ZA202211465B (en) | 2025-06-25 |
| ES3032247T3 (en) | 2025-07-16 |
| CN115667243B (zh) | 2025-01-07 |
| PH12022552775A1 (en) | 2024-03-25 |
| WO2021214470A1 (en) | 2021-10-28 |
| JP2023524206A (ja) | 2023-06-09 |
| GB202005863D0 (en) | 2020-06-03 |
| IL297434A (en) | 2022-12-01 |
| CN115667243A (zh) | 2023-01-31 |
| EP4139294A1 (en) | 2023-03-01 |
| CA3174361A1 (en) | 2021-10-28 |
| KR20230004720A (ko) | 2023-01-06 |
| MX2022013398A (es) | 2022-12-13 |
| EP4139294B1 (en) | 2025-04-09 |
| AU2021259366A1 (en) | 2022-11-10 |
| US20230167084A1 (en) | 2023-06-01 |
| JP7679400B2 (ja) | 2025-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11912703B2 (en) | 6-azaindole compounds | |
| KR102641030B1 (ko) | Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체 | |
| KR102755258B1 (ko) | Tlr 억제제로서 유용한 아미드 치환된 인돌 화합물 | |
| JP7549627B2 (ja) | Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 | |
| AU2017307208B2 (en) | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | |
| JP7382938B2 (ja) | ジアザインドール化合物 | |
| KR102714788B1 (ko) | Tlr 억제제로서 유용한 아미노 인돌 화합물 | |
| KR102473482B1 (ko) | [1,2,4]트리아졸로[1,5-a]피리디닐 치환된 인돌 화합물 | |
| JP7287964B2 (ja) | 置換インドールエーテル化合物 | |
| CA2903394C (en) | Arginine methyltransferase inhibitors and uses thereof | |
| CA3155569A1 (en) | Polyheterocyclic modulators of sting (stimulator of interferon genes) | |
| JP2018538269A (ja) | 免疫調節剤としての複素環化合物 | |
| KR20110137364A (ko) | 축합 피롤로피리딘 유도체 | |
| JP2021506889A (ja) | Ｔｌｒ阻害剤として有効な置換されたインドール化合物 | |
| JP2014111641A (ja) | Ａｘｌインヒビターとして有用なＮ３−ヘテロアリール置換トリアゾールおよびＮ５−ヘテロアリール置換トリアゾール | |
| UA121658C2 (uk) | Сполуки 5-хлордифторметоксифенілпіразолопіримідину як інгібітори янус-кінази | |
| JP7597709B2 (ja) | 置換インドールおよびインダゾール化合物 | |
| EP4225445A2 (en) | Heterocyclic inhibitors of egfr and/or her2, for use in the treatment of cancer | |
| KR102950614B1 (ko) | 항암제로서의 시클릭 디뉴클레오티드 | |
| WO2021074279A1 (en) | Spiro-fused tricyclic map4k1 inhibitors | |
| KR20220079587A (ko) | 치환된 카르바졸 화합물 | |
| JP6454346B2 (ja) | 芳香族複素環式化合物及び医薬におけるその応用 | |
| KR20230052930A (ko) | Tlr9의 억제제로서 유용한 치환된 헤테로아릴 화합물 | |
| AR117037A1 (es) | Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias | |
| AR127450A1 (es) | Moduladores del receptor ccr6 |